Chinese Drug Regulators Extend Rare Fast-track Approval For J&J Drug
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - In an extremely rare case of fast-track approval for a special class of medicines, Chinese drug regulators have given the green light for a Johnson & Johnson drug to be launched nationwide before the completion of clinical trials inside China